144 related articles for article (PubMed ID: 26377037)
1. Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma.
Verso M; Chiari R; Mosca S; Franco L; Fischer M; Paglialunga L; Bennati C; Scialpi M; Agnelli G
Thromb Res; 2015 Nov; 136(5):924-7. PubMed ID: 26377037
[TBL] [Abstract][Full Text] [Related]
2. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
[TBL] [Abstract][Full Text] [Related]
3. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
[TBL] [Abstract][Full Text] [Related]
4. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
5. Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
Ohba T; Toyokawa G; Osoegawa A; Hirai F; Yamaguchi M; Taguchi K; Seto T; Takenoyama M; Ichinose Y; Sugio K
Surg Today; 2016 Sep; 46(9):1091-8. PubMed ID: 26711128
[TBL] [Abstract][Full Text] [Related]
6. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
7. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
8. Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma.
Kang HJ; Lim HJ; Park JS; Cho YJ; Yoon HI; Chung JH; Lee JH; Lee CT
Respir Med; 2014 Feb; 108(2):388-94. PubMed ID: 24361161
[TBL] [Abstract][Full Text] [Related]
9. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
[TBL] [Abstract][Full Text] [Related]
10. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT.
Choi H; Paeng JC; Kim DW; Lee JK; Park CM; Kang KW; Chung JK; Lee DS
Lung Cancer; 2013 Mar; 79(3):242-7. PubMed ID: 23261227
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion gene.
Kometani T; Sugio K; Osoegawa A; Seto T; Ichinose Y
Thorac Cancer; 2018 May; 9(5):563-570. PubMed ID: 29517858
[TBL] [Abstract][Full Text] [Related]
12. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
13. [Oncogenic drivers in daily practice improve overall survival in patients with lung adenocarcinoma].
Fournier C; Greillier L; Fina F; Secq V; Nanni-Metellus I; Loundou A; Garcia S; Ouafik L; Tomasini P; Barlesi F
Rev Mal Respir; 2016 Nov; 33(9):751-756. PubMed ID: 27017063
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
[TBL] [Abstract][Full Text] [Related]
15. Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation.
Choi CM; Kim MY; Hwang HJ; Lee JB; Kim WS
Radiology; 2015 Apr; 275(1):272-9. PubMed ID: 25575117
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements.
Wu S; Wang J; Zhou L; Su D; Liu Y; Liang X; Zhang S; Zeng X
Thorac Cancer; 2015 Jul; 6(4):413-20. PubMed ID: 26273395
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement.
Hayashi H; Okamoto I; Kimura H; Sakai K; Nishimura Y; Nishio K; Nakagawa K
Anticancer Res; 2012 Oct; 32(10):4533-7. PubMed ID: 23060582
[TBL] [Abstract][Full Text] [Related]
19. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
Sun JM; Lira M; Pandya K; Choi YL; Ahn JS; Mao M; Han J; Park K; Ahn MJ; Kim J
Lung Cancer; 2014 Feb; 83(2):259-64. PubMed ID: 24300132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
